BPC-157 is not FDA approved, and research is ongoing
Note that creatine causes 2 to 4 pounds of intracellular water retention in muscle tissue, which will show on the scale but does not represent fat gain
RV-8451, differentiated oral, muscle-preserving GLP-1 candidate for obesity Recent Highlights: In February 2026, Rivus stated it was entering a pivotal year, advancing HU6 in the AMPLIFY Phase 2 MASH trial while preparing the first clinical trial for RV-8451, its muscle-preserving oral GLP-1 candidate, designed to address the muscle-loss criticism leveled at existing GLP-1 therapies
It is the rare, large harm that matters most, not the average week
1 So, how does L-carnitine work
Hypoglycemia can occur when these agents are combined with insulin or sulfonylureas